

# News Releases

All Years

Search

Go

[Advanced Search](#)

**MAY 8, 2024**

**Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger**

**FEB 28, 2024**

**Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results**

**JAN 23, 2024**

**Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to \$2.2B**

**NOV 9, 2023**

**Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights**

**NOV 2, 2023**

**Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma**

**OCT 18, 2023**

**Inhibrx Announces Participation in Upcoming Scientific Conferences**

**SEP 19, 2023**

**Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada**

**AUG 29, 2023**

**Inhibrx Announces \$200 Million Private Placement Financing**

**AUG 7, 2023**

**Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights**

**MAY 30, 2023**

**Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency**

**MAY 8, 2023**

**Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate Highlights**

**APR 26, 2023**

**Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBRX-109 DR5 Agonist Trials**

**MAR 6, 2023**

**Inhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Results**

**JAN 4, 2023**

**NorthStar Medical Radioisotopes and Inhibrx Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical Candidates**

**NOV 18, 2022**

**Inhibrx Announces Participation in Upcoming Investor Conference**

**NOV 16, 2022**

**Inhibrx Announces Updated Efficacy and Safety Data from the Expansion Cohorts in the Phase 1 Trial of INBRX-109 for the Treatment of Chondrosarcoma**

**NOV 7, 2022**

**Inhibrx Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights**

**OCT 20, 2022**

**Inhibrx Announces Participation in Upcoming Scientific Conferences**

**OCT 4, 2022**

**Inhibrx Announces Opportunity for Accelerated Approval Pathway on Functional AAT Serum Levels for INBRX-101 in AATD and Announces Bronchoalveolar Lavage Fluid Detection Results from the Phase 1 Study**

**OCT 3, 2022**

**Inhibrx To Host Webcast to Announce Regulatory Pathway for INBRX-101, its Optimized Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin Deficiency**

**AUG 15, 2022**

**European Medicines Agency Grants Orphan Drug Designation to INBRX-109 for the Treatment of Chondrosarcoma**

**AUG 8, 2022**


## **Inhibrx Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights**

**JUN 30, 2022**

## **Inhibrx Announces Completion of Phase 1 Combination Dose Escalation for INBRX-105, a Novel Targeted 4-1BB Agonist, and Draws an Additional \$60 Million from Oxford Finance**

**MAY 19, 2022**

## **Inhibrx Announces Details of Presentation at 2022 ASCO Annual Meeting**



**MAY 16, 2022**

## **INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates Potential to Achieve Normal Functional Alpha-1 Antitrypsin Levels with Monthly Dosing**

 [Photos \(2\)](#)

Show  per page

« 1 [2](#) [3](#) »



<https://inhibrx.investorroom.com/news-releases?l=25>